BCRX
BioCryst Pharmaceuticals Inc
8.50$
-0.6%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -251.9% | -1,030.0% | -65.6% | -196.0% | -95.8% | -91.0% | -922.2% | -685.2% | -5,387.7% | -15,372.8% | -244.9% | -35.1% | -36.9% | -21.7% | -45.0% | -164.2% | -142.2% | -153.1% | -283.3% | -27.2% | -202.8% | -163.4% | -448.2% | -183.4% | -770.4% | -90.4% | -59.8% | -28.7% | -11.5% | 37.7% | |
| 18.5% | 60.0% | 7.8% | 20.0% | 20.2% | 9.4% | 70.3% | 67.4% | 287.8% | 569.3% | 13.2% | 1.9% | 2.9% | 2.2% | 3.6% | 4.5% | 2.4% | 1.8% | 1.3% | 0.4% | 1.8% | 2.8% | 3.7% | 1.5% | 4.2% | 0.5% | 0.5% | 0.5% | 0.3% | 0.2% | |
| – | – | – | – | 3,152.6% | 1,105.0% | 6,773.1% | 7,324.1% | 152,100.2% | 17,378.4% | 53,747.5% | 7,988.8% | 10,361.6% | 7.4% | 9.9% | 24.3% | 15.8% | 25.2% | 74.8% | 20.1% | 32.2% | 50.1% | 45.5% | 36.3% | 83.1% | 22.0% | 16.5% | 16.8% | 14.5% | 9.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 44.7% | 18.7% | -5.6% | 35.8% | 21.3% | 29.2% | 53.9% | 50.6% | 37.0% | 86.6% | 21.0% | 52.4% | – | – | – | |
| 11.1% | -50.0% | -1.6% | -12.0% | 10.0% | 8.5% | -66.3% | 17.3% | 434.1% | 1,124.7% | 390.5% | -4.2% | -6.4% | -13.3% | -5.1% | 74.7% | -16.4% | 22.0% | 9.6% | 39.4% | -28.7% | 37.0% | -17.1% | -1.8% | 150.9% | 5.2% | -21.8% | -9.8% | -19.4% | -6.5% | |
| 11.1% | 110.0% | 6.3% | 40.0% | 82.1% | 23.3% | 23.0% | 3.2% | 81.9% | 327.4% | 24.7% | 4,693.9% | 2.1% | 0.8% | 0.5% | 0.3% | 0.4% | 0.2% | 0.8% | 10.6% | 20.0% | 1.3% | 1.8% | 0.7% | 2.9% | 1.5% | 0.5% | 0.7% | 0.2% | 0.3% | |
| -1,007.4% | 1,020.0% | 90.6% | -1,908.0% | 44.1% | 182.7% | 631.2% | 514.9% | -842.1% | -7,581.7% | -201.1% | -21.1% | 20.1% | -17.3% | 0.3% | 57.6% | 94.6% | -20.0% | -293.8% | -37.3% | 88.6% | -263.6% | 23.1% | 159.6% | -38.5% | 10.1% | -47.4% | -39.7% | 11.7% | -1.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -0.2% | 0.0% | -0.3% | 71.0% | 144.8% | 822.4% | 11.4% | 1.2% | 538.3% | 272.4% | 163.0% | 620.6% | 41.9% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 168.9% | 47.6% | 86.0% | 0.5% | 30.6% | 39.9% | 378.7% | 187.0% | 27.0% | 17.6% | -0.4% | -34.5% | |
| 1,166.7% | 20.0% | 107.8% | 1,960.0% | 46.4% | 1.7% | 6.9% | 55.1% | 6,375.4% | 36,333.5% | 47.7% | 93.7% | 1.2% | 64.2% | 1.3% | 120.9% | 64.5% | 174.7% | 822.4% | 11.4% | 88.4% | 538.8% | 302.6% | 202.9% | 1,699.4% | 228.8% | 32.5% | 9.8% | -1.3% | -38.0% | |
| -92.6% | 10.0% | 132.8% | -148.0% | -5.3% | 93.3% | -284.1% | -115.2% | 145.6% | 13,379.1% | -398.3% | 37.5% | -15.6% | 25.2% | -43.3% | 14.4% | 16.9% | 1.6% | 245.3% | -53.1% | -25.8% | 111.9% | -122.5% | 179.1% | 890.6% | 148.5% | -74.4% | -58.5% | -1.4% | -11.8% | |
| -263.0% | -1,140.0% | -71.9% | -236.0% | -178.0% | -114.4% | -945.2% | -688.4% | -5,469.6% | -15,700.2% | -269.6% | 4,658.8% | -39.0% | -22.6% | -45.5% | -164.5% | -142.7% | -153.3% | -284.1% | -37.8% | -222.8% | -164.7% | -450.0% | -184.1% | -773.2% | -92.0% | -60.3% | -29.4% | -11.8% | 37.4% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.